About Krux Pharma Private Limited
Data last updated:
Krux Pharma Private Limited is a private limited company based in Valsad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 October 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24302GJ2016PTC094103. Its GSTIN is 24AAGCK3251L1ZI (Gujarat).
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹3 Cr. It is led by directors Imran Shabbir Hussain Siroha and Salim Diwan Salaudeen Chopdar.
Its last annual general meeting (AGM) was held on 16 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Balda Industrial Park, Valsad, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹50.96 Cr, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹67.81 Lakh (net margin 1.3%) and EBITDA of ₹4.5 Cr (EBITDA margin 8.8%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years and 63% over five years.
The company has about 48 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹10.14 Cr and satisfied charges of ₹31.49 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kruxpharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressPlot No. 10 & 11 Survey No. 256/P1 Nr. Balda Industrial Parkvillage Balda, Ta. Pardi, Valsad, Gujarat, India – 396125
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Krux Pharma Private Limited
The main business activity of Krux Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Krux Pharma Private Limited FY 2024 filings available
Krux Pharma Private Limited reported revenue of ₹50.96 Cr (down 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Krux Pharma Private Limited
Revenue fell 2% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 63%. EBITDA fell 7% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Krux Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹50.96 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹4.5 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹67.81 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Krux Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.3% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Krux Pharma are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Krux Pharma Private Limited
Krux Pharma Private Limited is compared with the companies closest to it by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Therallen Pharma Private Limited | ₹52.29 Cr (FY 2025) | •••• | •••• | 34.0% | •••• | Hyderabad, Telangana, India |
| Infinita Biotech Private Limited | ₹52.26 Cr (FY 2024) | •••• | •••• | 119.0% | •••• | Vadodara, Gujarat, India |
| Ambe Phytoextracts Private Limited | ₹52.25 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Delhi, India |
| Micolube India Ltd | ₹52.22 Cr (FY 2024) | •••• | •••• | -14.0% | •••• | Delhi, India |
| Chemtek Scientific Private Limited | ₹52.2 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Thane, Maharashtra, India |
| Suboneyo Chemicals and Pharmaceuticals Private Limited | ₹52.16 Cr (FY 2025) | •••• | •••• | 20.0% | •••• | Jalgaon, Maharashtra, India |
| Amchem Products Private Limited | ₹52.15 Cr (FY 2025) | •••• | •••• | -15.0% | •••• | Greater Noida, Uttar Pradesh, India |
| Intracin Pharmaceuticals Private Limited | ₹52.07 Cr (FY 2024) | •••• | •••• | 39.0% | •••• | Nadiad, Gujarat, India |
| Sital Soap Packaging Private Limited | ₹52.05 Cr (FY 2024) | •••• | •••• | -40.0% | •••• | Raipur C.G, Chhattisgarh, India |
| Sheetal Medicare Products Limited | ₹52.04 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Wada, Maharashtra, India |
| Krux Pharma Private Limited this company | ₹50.96 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Valsad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Krux Pharma by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Krux Pharma Private Limited
Krux Pharma Private Limited is audited by G. B. LADDHA AND CO. LLP for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G. B. LADDHA AND CO. LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Krux Pharma Private Limited
Krux Pharma has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Imran Shabbir Hussain Siroha Also directs: Mitsu Healthcare Private Limited | Director | 17 Oct 2016 | 9 Years 11 Months | Current |
| Salim Diwan Salaudeen Chopdar Also directs: Mefree Lifescience LLP, Rajasthan Aushdhalaya Private Limited | Director | 18 Mar 2024 | 2 Years 6 Months | Current |
Ownership and Shareholding of Krux Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Krux Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Aug 2023 | Yes Bank Limited | ₹10.14 Cr | Open |
| 03 Jul 2021 | Hdfc Bank Limited | ₹11.59 Cr | Satisfied |
| 09 Oct 2018 | Indian Bank | ₹9.95 Cr | Satisfied |
| 05 Oct 2018 | Indian Bank | ₹9.95 Cr | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Krux Pharma Private Limited
Krux Pharma Private Limited has a workforce of 48 employees as of Nov 28, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Krux Pharma Private Limited
Krux Pharma Private Limited has 4 board changes on record since 2016: 2 appointments and 2 cessations. The latest: Salim Diwan Salaudeen Chopdar was appointed as Director on 18 Mar 2024.
4 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Krux Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Krux Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Krux Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Krux Pharma Private Limited
Krux Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAGCK3251L1ZI | Gujarat | Active | 08 Sep 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Krux Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Krux Pharma Private Limited
Krux Pharma is an active private limited company based in Valsad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 October 2016 (10+ years old) and is registered under CIN U24302GJ2016PTC094103.
Krux Pharma reported revenue of ₹50.96 Cr for FY 2025 (down 2% YoY).
Krux Pharma has 2 current directors:
- Imran Shabbir Hussain Siroha - Director
- Salim Diwan Salaudeen Chopdar - Director
Krux Pharma reported a net profit of ₹67.81 Lakh (net margin 1.3%) and EBITDA of ₹4.5 Cr (EBITDA margin 8.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Krux Pharma is 22% over three years and 63% over five years. In the latest year (FY 2025) revenue fell 2%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Krux Pharma is 24AAGCK3251L1ZI, registered in Gujarat.
The CIN (Corporate Identification Number) of Krux Pharma is U24302GJ2016PTC094103. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Krux Pharma was incorporated on 17 October 2016, making it 10+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of Krux Pharma by revenue are Therallen Pharma Private Limited, Infinita Biotech Private Limited, Ambe Phytoextracts Private Limited, Micolube India Ltd, Chemtek Scientific Private Limited and 5 more, all in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Salim Diwan Salaudeen Chopdar was appointed as Director on 18 Mar 2024. Digambar Jaikishan Zawar ceased to be Director on 01 Jul 2021. Mahboob Diwan Chopdar ceased to be Additional Director on 28 Dec 2020. Krux Pharma has 4 board changes on record in total.
Krux Pharma can be reached through the website kruxpharma.com. Its registered office is in Valsad, Gujarat, India.